Chronic-Dose Safety and Efficacy Study of Albuterol-HFA-BAI in Pediatric Asthmatics

NCT ID: NCT00308685

Last Updated: 2022-04-01

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

95 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-06-10

Study Completion Date

2006-12-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to evaluate the repeat-dose safety and effectiveness of a bronchodilator inhaler relative to placebo (inactive drug inhaler) in children aged 4-11 years with asthma. The dosing period lasts three weeks and starts following a three-week run-in period.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Albuterol-HFA-BAI

ProAir(TM) HFA, Breath Actuated Inhalation Aerosol

Group Type EXPERIMENTAL

Albuterol

Intervention Type DRUG

Albuterol 90mcg

Placebo-HFA-BAI

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Albuterol

Albuterol 90mcg

Intervention Type DRUG

Placebo

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Persistent asthma of a minimum of six months duration that has been stable for at least four weeks prior to screening
* Male and female children aged 4-11 years, inclusive, with predicted forced expiratory volume in 1 second (FEV1) 60-90%
* Ability to perform spirometry
* Demonstrate 12% airways reversibility

Exclusion Criteria

* Require continuous treatment with beta-blockers, monoamine oxidase inhibitors, tricyclic antidepressants, anticholinergics, and/or systemic corticosteroids
* Presence of any non-asthmatic clinically-significant acute or uncontrolled chronic diseases
Minimum Eligible Age

4 Years

Maximum Eligible Age

11 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Teva Medical Expert, M.D.

Role: STUDY_DIRECTOR

Teva Branded Pharmaceutical Products R&D, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Little Rock Allergy and Asthma

Little Rock, Arkansas, United States

Site Status

Allergy & Asthma Specialist Medical Group

Huntington Beach, California, United States

Site Status

Allergy & Asthma Associates of Santa Clara Valley Research Center

San Jose, California, United States

Site Status

William Storms Medical Research

Colorado Springs, Colorado, United States

Site Status

Colorado Allergy and Asthma Centers, PC

Denver, Colorado, United States

Site Status

Colorado Allergy and Asthma Centers, PC

Englewood, Colorado, United States

Site Status

Colorado Allergy and Asthma Centers, PC

Lakewood, Colorado, United States

Site Status

Southern Allergy & Asthma, PC

Savannah, Georgia, United States

Site Status

Sneeze, Wheeze & Itch Associates, Inc.

Normal, Illinois, United States

Site Status

Clinical Research Institute

Minneapolis, Minnesota, United States

Site Status

The Asthma & Allergy Center, PC

Papillion, Nebraska, United States

Site Status

Allergy and Respiratory Center

Canton, Ohio, United States

Site Status

Allergy, Asthma & Clinical Research Center

Oklahoma City, Oklahoma, United States

Site Status

Pediatric Pulmonary Associates of North Texas

Dallas, Texas, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IXR-303-25-167

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.